Chris MacDonald

Chris MacDonald

InvestorPlace Contributor

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

Rivian Stock Forecast: Can RIVN Bypass Short-Term Hurdles to Become a Long-Term Winner?

By Chris MacDonald, InvestorPlace Contributor

Let's dive into whether RIVN stock is worth considering at current levels, or if this EV company could be poised for more downside from here.

Nvidia Stock Analysis: One Reason to Buy, One Reason to Sell

By Chris MacDonald, InvestorPlace Contributor

Let's dive into whether Nvidia stock is a buy or sell given its incredible run higher and the extreme volatility it's seen.

3 Stocks Gemini AI Thinks Could Be the Next Big Thing

By Chris MacDonald, InvestorPlace Contributor

Let's dive into three top Gemini AI stock predictions that could propel investor portfolios to the next level.

3 Financial Stocks to Buy in August and Add on Dips

By Chris MacDonald, InvestorPlace Contributor

Here are three top financial stocks to buy in August, particularly if we get any dips tied to the macroeconomic outlook.

Why is Immuneering (IMRX) Stock Up 24% Today?

By Chris MacDonald, InvestorPlace Contributor

Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus.

Load More